• HUTCHMED's sovleplenib received FDA orphan drug designation for primary immune thrombocytopenia, potentially providing seven years of US market exclusivity upon approval.
• The once-daily oral Syk inhibitor also qualifies for clinical trial tax credits, fee waivers and specialized FDA guidance.
• Chinese applications for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia remain under review, supported by positive pivotal trial results.
• ESLIM-01 supported the thrombocytopenia application; ESLIM-02 supported the anemia application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261029-12386923), on October 29, 2026, and is solely responsible for the information contained therein.